Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.

Bartlett, Nancy L

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. [electronic resource] - Leukemia & lymphoma 07 2017 - 1607-1616 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

1029-2403

10.1080/10428194.2016.1256481 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Biomarkers
Brentuximab Vedotin
Drug Resistance, Neoplasm
Female
Humans
Immunoconjugates--administration & dosage
Immunohistochemistry
Ki-1 Antigen--metabolism
Lymphoma, Large B-Cell, Diffuse--diagnosis
Male
Middle Aged
Neoplasm Staging
Recurrence
Retreatment
Treatment Outcome
Young Adult